Introduction {#S0001}
============

Crohn's disease (CD) has been geographically varied and relatively rare in Asian region whereas North American and European Caucasians had a higher incidence and prevalence than the rest of the world.[@CIT0001] The incidence rate of CD varied across countries in Asia, ranging from 0.07 to 3.12 per 100,000 people,[@CIT0002]--[@CIT0007] compared with the worldwide incidence of CD that varied from 0.1 to 16 per 100,000 population.[@CIT0008],[@CIT0009] While the prevalence of CD could be as high as 18.6 per 100,000 population in Hong Kong,[@CIT0007] it is still significantly less than Western countries.

Despite the epidemiological information presented above, clinical outcomes of CD have been dominated by evidence from the Caucasian population in developed countries. Ten-year survival rates varied from 90% (Italy),[@CIT0010] 91% (Denmark),[@CIT0011] 95% (United Kingdom),[@CIT0012] 96% (Sweden)[@CIT0013] to 99% Australia.[@CIT0014] Before the introduction of infliximab, two large Swedish cohorts reported 96% 10-year[@CIT0013] and 94% 15-year[@CIT0015] survival rates, respectively. Longer-term survival data at 30 years of 93% and 73% were based on Australia[@CIT0014] and the US studies.[@CIT0016] The survival rates reported by these countries might reflect not only varying genotype characteristics, clinical response of the patients, but also the health care services provided to them.

Attempt to include non-Caucasian subjects in developed countries had not been able to gain a sufficient number of sample for statistical inference and therefore was excluded from the analysis of clinical outcomes.[@CIT0012] To date, three major Asian studies have been conducted. In the Asia-Pacific Crohn's and Colitis Epidemiology Study (ACCESS), 166 new CD patients in 8 countries were reported (incidence 0.54 per 100,000 population).[@CIT0006] In alarge population-based epidemiological study conducted in Hong Kong, an accumulated 983 CD cases were assessed but no clinical outcomes were reported.[@CIT0007] To date, the largest non-Caucasian clinical data of IBD is the ACCESS cohort, but less than 200 CD cases were included in its early phase.[@CIT0017]

This study was aimed to report clinical characteristics including disease severity and complication at presentation and outcomes of 287 domestic and international patients who visited our institution.

Materials and methods {#S0002}
=====================

We reviewed demographics, clinical characteristics, investigation results and clinical outcomes in medical records of all patients who visited Bumrungrad International Digestive Disease Center (BIDDC) during 2005--2010. Colonoscopy and sigmoidoscopy were performed in compliance with the American Society for Gastrointestinal Endoscopy (ASGE) practice guidelines.

Patient ethnicities were arbitrarily categorized into 3 groups: Asian (Thai, Oriental Non-Thai, South Asian), Middle Eastern and Caucasian. Disease severity was classified based on pathological findings into inactive, mild, moderate and severe using the modified Riley Histopathological Activity Score. The need for surgical consultation was based on the content of relevant operative note in the medical record. The follow-up period was estimated from the date of CD diagnosis and date of last follow-up visit.

Descriptive statistics were used where appropriate. Association between categorical variables was analyzed using chi-square test or Fischer's exact test. Association between categorical and interval variables was analyzed using Student's *t*-test and/or analysis of covariance (ANOVA) where appropriate.

Ethical considerations {#S0003}
======================

This study was approved by Bumrungrad International Institutional Review Board (BI/IRB No.146-09-11). This study was performed in compliance with the Declaration of Helsinki, the CIOMS International Guidelines for Ethical Review of Epidemiological Studies, as well as applicable Thai laws. The patient consent to review their medical records was not required because the written informed consent was very unlikely obtainable in this retrospective study and that re-contacting these patients to obtain consent may lead to privacy breach. Patient data were stored electronically within our secured hospital information system. The data could be accessed only by authorized health professionals using their own staff codes. Patient's name and identification number were omitted and rendered anonymous before data analysis.

Results {#S0004}
=======

As many as 262,606 individuals visited BIDDC during 2005--2010. The distribution of patients' ethnicity visiting the BIDDC was slightly different from hospital patient ethnic profiles (Thai:Non-Thai = 60:40).

A total of 287 CD patients were followed up for 5.65 years on average (95% CI: 4.92 to 6.39). Forty-twopercent were Middle Eastern (41.80%), followed by Caucasian (29.62%) and Asian (28.57%). Data presented in [Table 1](#T0001){ref-type="table"} suggested that Middle Eastern and Caucasian had significantly higher prevalence of CD than that of Asian patients (286.71 and 278.66, respectively, vs 43.10 per 100,000 population).Table 1Ethnicity distribution of Crohn's disease and total gastrointestinal patients (2005--2010)Ethnicity200520062007200820092010TotalCrohnInstitution-Specific Prevalence (per 100,000)Asian26,48229,03629,31934,00435,40436,005190,2508243.10Middle Eastern4,5675,8316,4187,8287,7269,48341,853120286.71Caucasian4,0884,7125,2645,2095,6585,57230,50385278.66Total35,13739,57941,00147,04148,78851,060262,606287109.29

While most of the cases were male (58.89%), there was significant variation in gender distribution (*p*=0.001): Asian male 39.02%, compared with 65.83% Middle Eastern and 68.24% Caucasian male. The overall mean age was 39.46 years with significant variation across ethnic origins (*p*\<0.001), ranging from 32.88 (Middle East) to 43.35 (Asian) and 45.00 (Caucasian) years. Only 8.74% of the cases reported that they smoked at least 100 cigarettes in life.

Sixty-seven percent of the patients presented with no more than oneyear of symptoms. Patients experienced CD symptoms for amean of 18.41 months (95% CI 13.62--23.20) before seeking for medical attention. Middle Eastern patients were more likely to have symptoms for more than two years (26.55 months), as compared to Caucasian (11.98 months) and Asian patients (12.35 months) (*p*=0.0008).

One-third of the patients (32.00%) had only perianal lesions whereas 28.67%, 20.00%, 19.33% had ileitis, ileocolitis and colitis, respectively. Only 9.76% of Asian patients had perianal lesions, compared with 24.17% and 12.94% of Middle Eastern and Caucasian patients, respectively. The proportions of perianal lesions were statistically different across ethnic origins (*p*=0.014).

Half of the patients (49.48%) had mildly active CD whereas 11.50% were severely active. Fifteen out of 85 (17.65%) Caucasian patients were severely active, compared with Middle Eastern (10.83%), and Asian (6.10%). Penetrative CD was identified in 7 patients (1 entero-vesical, 2 entero-enteral, 3 intra-abdominal, 1perineal fistula, 2 recto-vaginal and 3 entero-cutaneous fistula).

As immunosuppressive drug and biologic agent were used in only 14.98% and 5.92%, respectively, the need for steroid was used to determine disease exacerbation. Of 254 non-severe cases (88.50%), 34.65 eventually received steroids during the study period, suggesting that disease progression existed among one-third of the patients who initially had non-severe pathology. The disease progression significantly varied across ethnic groups, from 19.63% of Middle Eastern cases, to 40.00% and 50.65% of Caucasian and Asian patients, respectively (*p*\<0.0001).

Clinical improvement was observed in 82.16% of the patients. However, 75 patients required surgery and hospitalization with significant ethnic variation (37.65% of Caucasian, 28.33% of Middle Eastern and 10.98% of Asian; *p*\<0.0001).

Extra-intestinal manifestations were found in 18 cases (6.27%): 1 erythema nodosum, 2 psoriasis, 1 arthritis, 4 non-specific arthralgia, 4 oropharyngeal ulcer, 5 osteoporosis or osteomalacia, 1 primary sclerosing cholangitis. Penetrating disease was found in 7 cases (2.52%): 4 Middle Eastern, 2 Caucasian and 1 Asian. Fourteen patients had single lesion: 1 entero-vesical, 2 entero-enteral, 3 intraabdominal, 1perineal, 2 recto-vaginal, 3 entero-cutaneous fistula. One Middle Eastern patient had six fistula lesions. Colon cancer was developed in one Asian and one Caucasian patients who were severely and moderately active, respectively.

Discussion {#S0005}
==========

Given relatively equal proportions of Caucasian, Asian and Middle Eastern patients with CD in a single institution, findings from our study added comparative analysis of clinical characteristics and outcomes across major ethnic origins. Some important factors including ethnicity, age and gender should also be considered as part of the CD activity discussed below.

The CD prevalence of Middle Eastern and Caucasian patients was six times more than that of Asian patients. Although the institution-specific prevalence was relatively much higher than that of population-based studies and could not be generalizable to the population, the findings were comparatively proportional to previous Middle Eastern and Asian studies. The prevalence of CD ranged from 53.1 to 65.1 per 100,000 Middle Eastern population,[@CIT0018]--[@CIT0020] compared with 1.3 to 18.6 per 100,000 in Hong Kong,[@CIT0007],[@CIT0021] 5.8 to 13.5 per 100,000 Japanese,[@CIT0002],[@CIT0003] 11.2 per 100,000 Korean[@CIT0005] and 7.2 per 100,000 Singaporean population. Nonetheless, the significant variation of CD prevalence in the Caucasian population from 40 to 54 per 100,000 in Europe,[@CIT0022],[@CIT0023] 162--201 per 100,000 in North America,[@CIT0024],[@CIT0025] 214 per 100,000 in the United Kingdom[@CIT0026] made it difficult to compare with that of the Asian population. While the ACCESS study reported that CD was more common in Asia than Australia,[@CIT0017] this study added evidence from Middle Eastern and non-Australian Caucasian.

Our data suggested that age and gender effects on the disease prevalence might be different across ethnic origins. In contrast to the finding from Hong Kong registry, CD was not male predominant among our Asian patients (male:female ratio = 0.64 vs 1.86).[@CIT0007] As a comparable number of male and female patients visited our hospital, gender could not account for the differential prevalence of CD between male and female. The age difference across patient ethnic groups might reflect differential accessibility to health services at a facility for medical tourism. At our institution, Middle Eastern patients were more likely to get medical expenses covered by their government and, therefore, much less financial barriers to the diagnosis and treatment of their health problems. The majority of them expressed relatively higher trust in our medical facility than that in their own countries. On the contrary, most Caucasian patients were expatriates who usually have health insurance from their countries that covered medical expense abroad upon request.

Our patients from any ethnic origin had three times longer duration of symptoms before final diagnosis of CD than the previously reported median time of 5.5 months in ACCESS study.[@CIT0006] It is possible that local doctors had already managed patients with short duration of symptom whereas those with longer duration had to seek medical care abroad. Further study is required to test this hypothesis. Interestingly, Middle Eastern patients had more than two years of symptoms before seeking medical care. Although anecdotal data from an informal interview with the patients suggested how much they trust their own health care system, more evidence is needed to get a better understanding of this phenomenon.

Overlapping terms/concepts of severity have been used in existing literature with inconclusive definitions. In our study, pathological severity (inactive, mild, moderate and severe)[@CIT0027] was used as a baseline reference for clinical improvement assessment in the subsequent visits. In other studies, anatomical aspect was used as aseverity criteria, so having perianal lesion was considered worse disease behavior.[@CIT0017] A relatively large proportion of isolated perianal CD lesions, along with the significantly different prevalence of isolated perianal lesions across ethnic origins, suggested that perianal CD could be regarded as a "type" rather than a "complication" of CD. The perianal lesion should, therefore, be categorized as disease location (L5), not disease behavior presented in some large study like ACCESS.[@CIT0017]

Findings from our study suggested that some demographic variables, especially ethnicity, age and gender, could be useful and simple enough for disease severity determination. Existing clinical scores for CD such as Crohn's Disease Activity Index (CDAI) has been introduced in 1976[@CIT0028] with no major modification since then. CDAI comprised 8 (4 symptom-related, 1 sign-related, 1 laboratory, 1 physiological and 1 medication-related) items. Likewise, the Harvey-Bradshaw Index Score comprised 5 simplified items selected from the CDAI.[@CIT0029] Both scores did not take ethnicity and age into account whereas gender was only indirectly incorporated into the CDAI formula as a reference for hematocrit determination. Further study to compare the scores across these variables should be conducted.

The need for immunosuppressive drugs including steroids, azathioprine and other biologic agents as well as the need for surgery have been used to reflect disease severity. However, in some settings like ours, these medications have not been common; pathological findings are therefore crucial for the determination of disease severity. Instead, the need for these medications was used to determine disease progression in our patients. The variation of disease progression across patients from various ethnic origins should be considered at the initial discussion with apatient. For example, Asian patients are less likely to have severe CD at presentation than Caucasian patients but they are more likely to get immunosuppressive drugs or biologic agents but less likely to be operated.

As a tertiary-level hospital for medical tourism that provides care to arelatively wealthy group of domestic and international patients, some findings from this study, especially the clinical outcomes, might not be generalized to the population.

Conclusions {#S0006}
===========

Crohn's disease prevalence, gender, age, duration of symptoms, perianal lesion, pathological severity and disease progression varied across ethnic origins.
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